{
  "drug_name": "(3,4-Dihydroxy-Phenyl)-Triphenyl-Arsonium",
  "generic_name": [
    "METHENAMINE, BENZOIC ACID, PHENYL SALICYLATE, METHYLENE BLUE, AND HYOSCYAMINE SULFATE"
  ],
  "brand_names": [
    "URIBEL TABS"
  ],
  "drug_interactions": [],
  "warnings": [
    "WARNINGS Do not exceed recommended dosage. If rapid pulse, dizziness or blurring of vision occurs, discontinue use immediately."
  ],
  "adverse_reactions": [],
  "contraindications": [
    "CONTRADICTIONS Hypersensitivity to any of the ingredients is possible. Risk benefits should be carefully considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis, acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy)."
  ],
  "dosage_administration": [
    "DOSAGE AND ADMINISTRATION Adults One tablet orally 4 times per day followed by liberal fluid intake. Older Children Dosage must be individualized by physician. Not recommended for use in children six years of age or younger."
  ],
  "indications": [
    "INDICATIONS AND USAGE Uribel Tabs are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."
  ],
  "fetched_at": "2025-10-01T02:42:34.326491",
  "source": "OpenFDA"
}